Eiger BioPharmaceuticals's EBIT per Share for the
three
months ended in Dec. 2023 was $-8.13.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-47.08.
During the past 3 years, the average EBIT per Share Growth Rate was 9.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 13.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 27.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Eiger BioPharmaceuticals's EBIT per Share or its related term are showing as below:
EIGRQ'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -46.4 Med: 19 Max: 60.7
Current: 9.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Eiger BioPharmaceuticals was 60.70% per year. The lowest was -46.40% per year. And the median was 19.00% per year.
EIGRQ's 3-Year EBIT Growth Rate is ranked better than 57.89% of 1311
companies
in the Biotechnology industry
Industry Median: 3.6
vs EIGRQ: 9.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eiger BioPharmaceuticals (OTCPK:EIGRQ) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Eiger BioPharmaceuticals EBIT per Share Related Terms
Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Business Description
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EIGRQ has been successfully added to your 